Anaplastic Thyroid Cancer - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
76 Pages - GMD12063
$2,000.00

Summary

Global Markets Direct’s, ‘Anaplastic Thyroid Cancer - Pipeline Review, H1 2014’, provides an overview of the Anaplastic Thyroid Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anaplastic Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Anaplastic Thyroid Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Anaplastic Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anaplastic Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Thyroid Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anaplastic Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anaplastic Thyroid Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Anaplastic Thyroid Cancer - Overview 7
Pipeline Products for Anaplastic Thyroid Cancer - Comparative Analysis 8
Anaplastic Thyroid Cancer - Therapeutics under Development by Companies 9
Anaplastic Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 11
Anaplastic Thyroid Cancer - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Anaplastic Thyroid Cancer - Products under Development by Companies 16
Anaplastic Thyroid Cancer - Products under Investigation by Universities/Institutes 17
Anaplastic Thyroid Cancer - Companies Involved in Therapeutics Development 18
Plexxikon Inc. 18
Exelixis, Inc. 19
OXiGENE, Inc. 20
Genelux Corporation 21
Immune Pharmaceuticals, Inc. 22
Anaplastic Thyroid Cancer - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 27
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
fosbretabulin tromethamine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
cabozantinib s-malate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
crolibulin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
GLONC-2 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
PLX-4720 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CLM-3 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CLM-94 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AY-4 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Anaplastic Thyroid Cancer - Recent Pipeline Updates 50
Anaplastic Thyroid Cancer - Discontinued Products 68
Anaplastic Thyroid Cancer - Product Development Milestones 69
Featured News & Press Releases 69
Jun 10, 2013: Oxigene Announces Publication Of Final FACT Study Data Of Zybrestat In Patients With Anaplastic Thyroid Cancer In Journal Thyroid 69
Feb 14, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains FDA Orphan Drug Status 70
Jan 08, 2013: Combination Of Pazopanib And Paclitaxel May Slow Anaplastic Thyroid Cancer, Mayo Clinic Study Shows 70
Sep 17, 2012: OXiGENE Announces Agreement With FDA On Special Protocol Assessment For Phase III Trial Of Zybrestat In Anaplastic Thyroid Cancer 71
Sep 07, 2012: Oxigene To Present Data Showing Importance Of Local Site Pathology Confirmation In Phase II/III Clinical Trial Of Zybrestat In Anaplastic Thyroid Cancer 71
Sep 02, 2012: Azanta Pharma And Lavi Enter Into Agreement To Provide Zybrestat In Israel On Compassionate Use Basis 72
Aug 22, 2012: OXiGENE Expands ZYBRESTAT Named Patient Program With Azanta 73
Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer 73
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76

List of Tables
Number of Products under Development for Anaplastic Thyroid Cancer, H1 2014 7
Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Anaplastic Thyroid Cancer - Pipeline by Plexxikon Inc., H1 2014 18
Anaplastic Thyroid Cancer - Pipeline by Exelixis, Inc., H1 2014 19
Anaplastic Thyroid Cancer - Pipeline by OXiGENE, Inc., H1 2014 20
Anaplastic Thyroid Cancer - Pipeline by Genelux Corporation, H1 2014 21
Anaplastic Thyroid Cancer - Pipeline by Immune Pharmaceuticals, Inc., H1 2014 22
Assessment by Monotherapy Products, H1 2014 23
Number of Products by Stage and Target, H1 2014 26
Number of Products by Stage and Mechanism of Action, H1 2014 29
Number of Products by Stage and Route of Administration, H1 2014 32
Number of Products by Stage and Molecule Type, H1 2014 34
Anaplastic Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2014 50
Anaplastic Thyroid Cancer - Discontinued Products, H1 2014 68

List of Figures
Number of Products under Development for Anaplastic Thyroid Cancer, H1 2014 7
Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 23
Number of Products by Top 10 Target, H1 2014 24
Number of Products by Stage and Top 10 Target, H1 2014 25
Number of Products by Top 10 Mechanism of Action, H1 2014 27
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 28
Number of Products by Top 10 Route of Administration, H1 2014 31
Number of Products by Stage and Top 10 Route of Administration, H1 2014 32
Number of Products by Top 10 Molecule Type, H1 2014 33
Number of Products by Stage and Top 10 Molecule Type, H1 2014 34

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax